COSMOS Pharmaceutical Corporation

CSMYFOTCHealthcare● Active

$41.20

+$4.14(+11.17%)

Market Cap$3.3B

P/E Ratio—

52W High$48.271

52W Low$37.06

Avg Volume9

Open$41.20

Beta0.14

Overview

COSMOS Pharmaceutical Corporation (CSMYF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CSMYF · free cash flow · updated Jun 9, 2026

Core FCF metrics

CSMYF · FCF · TTM · margin & CAGR

Free cash flow was −$859.0M for FY2025 (fiscal year ending 2025-05-31), down 35.3% year-over-year The FCF margin was -0.1%.

FY2025 Free Cash Flow−$859.0M▼ -35.3% YoY

Trailing 12M (TTM)$0trailing 4 quarters sum

FCF Margin-0.1%−$859.0M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CSMYF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$52.47B(53.33B)−$859.0M▼ 35.3%-0.1%

FY2024$55.17B(55.81B)−$635.0M▼ 108.1%-0.1%

FY2023$54.43B(46.64B)$7.80B▲ +169.0%0.9%

FY2022$32.19B(43.50B)−$11.30B▼ 724.1%-1.5%

FY2021$27.88B(26.06B)$1.81B▼ 95.4%0.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CSMYF · P/FCF · FCF yield · FCF per share

COSMOS Pharmaceutical Corporation (CSMYF) reported negative free cash flow of −$0.86B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-05-31

Cash flow statement summary

CSMYF · cash flow statement · operating / investing / financing

For FY2025, COSMOS Pharmaceutical Corporation generated $52.47B in operating cash flow and spent 53.33B in capital expenditures, yielding −$859.0M in free cash flow.

Operating Activities

+$52.47B

Cash from core business operations

2025-05-31

Investing Activities

−$55.45B

CapEx, acquisitions & investments

2025-05-31

Financing Activities

+$7.72B

Buybacks, dividends & debt

2025-05-31

FCF FormulaOperating CF ($52.47B) − |CapEx| (53.33B) = FCF (−$859.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CSMYF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

COSMOS Pharmaceutical CorporationYOU

CSMYF

−$859.0M-35.3%-0.1%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

COSMOS Pharmaceutical Corporation (CSMYF) reported free cash flow of −$859.0M for FY2025 (fiscal year ending 2025-05-31), down 35.3% year-over-year. The FCF margin was -0.1%.

Based on available data, COSMOS Pharmaceutical Corporation has maintained positive free cash flow for at least 10 fiscal year(s). FCF peaked at $39.51B in FY2020.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CSMYF free cash flow · 8 questions

COSMOS Pharmaceutical Corporation free cash flow was −$859.0M for FY2025, down 35.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $0.

CSMYF free cash flowCSMYF FCFCSMYF FCF 2025CSMYF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · COSMOS Pharmaceutical Corporation · COSMOS Pharmaceutical Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026